| NCT04429542 |
Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT04429542 |
Recruiting |
Bicara Therapeutics |
2022-12-31 |
| NCT04375384 |
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer |
https://ClinicalTrials.gov/show/NCT04375384 |
Recruiting |
Wake Forest University Health Sciences |
2022-01-31 |
| NCT04220866 |
Study of Intratumoral (IT) MK-1454 in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002) |
https://ClinicalTrials.gov/show/NCT04220866 |
Recruiting |
Merck Sharp & Dohme Corp. |
2023-09-28 |
| NCT04128696 |
Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT04128696 |
Recruiting |
GlaxoSmithKline |
2023-07-28 |
| NCT04032704 |
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT04032704 |
Recruiting |
Seattle Genetics, Inc. |
2021-07-31 |
| NCT03957096 |
A Safety Study of SGN-CD47M in Patients With Solid Tumors |
https://ClinicalTrials.gov/show/NCT03957096 |
Recruiting |
Seattle Genetics, Inc. |
2022-03-31 |
| NCT03829436 |
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers |
https://ClinicalTrials.gov/show/NCT03829436 |
Recruiting |
Tempest Therapeutics |
2022-02-18 |
| NCT03485209 |
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors |
https://ClinicalTrials.gov/show/NCT03485209 |
Recruiting |
Seattle Genetics, Inc. |
2021-06-30 |
| NCT03409458 |
A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab |
https://ClinicalTrials.gov/show/NCT03409458 |
Recruiting |
Phosplatin Therapeutics |
2020-02-01 |
| NCT03389477 |
Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03389477 |
Recruiting |
Washington University School of Medicine |
2021-06-30 |
| NCT03383094 |
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT03383094 |
Recruiting |
University of California, San Diego |
2021-04-30 |
| NCT03381183 |
IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03381183 |
Recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2021-12-31 |
| NCT03370276 |
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03370276 |
Recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2021-12-31 |
| NCT03823131 |
Tavo With Electroporation, Pembrolizumab, and Epacadostat in Patients With Unresectable Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT03823131 |
Recruiting |
University of California, San Francisco |
2022-01-01 |
| NCT03356587 |
A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy |
https://ClinicalTrials.gov/show/NCT03356587 |
Recruiting |
Seoul National University Hospital |
2020-01-01 |
| NCT03341936 |
Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN |
https://ClinicalTrials.gov/show/NCT03341936 |
Recruiting |
Dana-Farber Cancer Institute |
2021-06-30 |
| NCT03340896 |
Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT |
https://ClinicalTrials.gov/show/NCT03340896 |
Recruiting |
Groupe Oncologie Radiotherapie Tete et Cou |
2026-09-24 |
| NCT03340038 |
Use of a Non-ICU Specialty Ward For Immediate Post-operative Management of Head and Neck Free Flaps |
https://ClinicalTrials.gov/show/NCT03340038 |
Completed |
University of California, Davis |
2019-02-11 |
| NCT03336606 |
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma |
https://ClinicalTrials.gov/show/NCT03336606 |
Recruiting |
Providence Health & Services |
2022-07-01 |
| NCT03330249 |
Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion |
https://ClinicalTrials.gov/show/NCT03330249 |
Active, not recruiting |
Groupe Oncologie Radiotherapie Tete et Cou |
2020-07-31 |
| NCT03319459 |
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03319459 |
Active, not recruiting |
Fate Therapeutics |
2021-10-31 |
| NCT03313804 |
Priming Immunotherapy in Advanced Disease With Radiation |
https://ClinicalTrials.gov/show/NCT03313804 |
Recruiting |
University of Kentucky |
2020-09-30 |
| NCT03311334 |
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03311334 |
Recruiting |
Boston Biomedical, Inc |
2021-11-30 |
| NCT03291002 |
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC |
https://ClinicalTrials.gov/show/NCT03291002 |
Recruiting |
CureVac AG |
2022-10-31 |
| NCT03283605 |
Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas |
https://ClinicalTrials.gov/show/NCT03283605 |
Recruiting |
Centre hospitalier de l’Université de Montréal (CHUM) |
2020-03-31 |
| NCT03281499 |
Transoral Robotic Surgery and Tailored Radiotherapy in Unknown Primary and Small Squamous Cell Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT03281499 |
Active, not recruiting |
University Health Network, Toronto |
2020-08-31 |
| NCT03268993 |
Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT03268993 |
Recruiting |
University of Pittsburgh |
2022-12-31 |
| NCT03260023 |
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers Including Oropharyngeal SCCHN |
https://ClinicalTrials.gov/show/NCT03260023 |
Recruiting |
Transgene |
2020-12-31 |
| NCT03254927 |
A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03254927 |
Recruiting |
Celldex Therapeutics |
2020-07-31 |
| NCT03247712 |
Neoadjuvant Immunoradiotherapy in Head & Neck Cancer |
https://ClinicalTrials.gov/show/NCT03247712 |
Recruiting |
Providence Health & Services |
2025-12-31 |
| NCT03247309 |
TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) |
https://ClinicalTrials.gov/show/NCT03247309 |
Recruiting |
Immatics US, Inc. |
2020-12-31 |
| NCT03238365 |
Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT03238365 |
Active, not recruiting |
Thomas Jefferson University |
2019-07-30 |
| NCT03236935 |
Phase Ib of L-NMMA and Pembrolizumab |
https://ClinicalTrials.gov/show/NCT03236935 |
Recruiting |
The Methodist Hospital System |
2020-01-01 |
| NCT03229278 |
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma |
https://ClinicalTrials.gov/show/NCT03229278 |
Active, not recruiting |
Rutgers, The State University of New Jersey |
2022-07-30 |
| NCT03228667 |
QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer |
https://ClinicalTrials.gov/show/NCT03228667 |
Recruiting |
Altor BioScience |
2021-06-30 |
| NCT03226756 |
Nivolumab in Recurrent and/or Metastatic SCCHN |
https://ClinicalTrials.gov/show/NCT03226756 |
Active, not recruiting |
UNICANCER |
2017-12-31 |
| NCT03212469 |
A Trial of Durvalumab and Tremelimumab in Comibination With SBRT in Patients With Metastatic Cancer |
https://ClinicalTrials.gov/show/NCT03212469 |
Recruiting |
Gustave Roussy, Cancer Campus, Grand Paris |
2019-06-30 |
| NCT03196869 |
the Study of Effect of Chronomodulated Chemotherapy on the Dendritic Cells Subsets in the Treatment of Advanced Nasopharyngeal Cancer |
https://ClinicalTrials.gov/show/NCT03196869 |
Recruiting |
Guiyang Medical University |
2019-04-12 |
| NCT03196843 |
Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC. |
https://ClinicalTrials.gov/show/NCT03196843 |
Recruiting |
The First Affiliated Hospital of Dalian Medical University |
2020-08-31 |
| NCT03195699 |
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers |
https://ClinicalTrials.gov/show/NCT03195699 |
Recruiting |
Tvardi Therapeutics, Incorporated |
2020-07-31 |
| NCT03194373 |
Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03194373 |
Completed |
University of Michigan Rogel Cancer Center |
2019-02-01 |
| NCT03182959 |
Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer |
https://ClinicalTrials.gov/show/NCT03182959 |
Active, not recruiting |
University of Arizona |
2021-12-31 |
| NCT03134846 |
Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate |
https://ClinicalTrials.gov/show/NCT03134846 |
Recruiting |
University Medical Center Groningen |
2021-01-31 |
| NCT03129061 |
Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
https://ClinicalTrials.gov/show/NCT03129061 |
Active, not recruiting |
CellSight Technologies, Inc. |
2021-04-30 |
| NCT03117257 |
Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced SCCHN |
https://ClinicalTrials.gov/show/NCT03117257 |
Recruiting |
Guiyang Medical University |
2019-08-19 |
| NCT03109158 |
NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT03109158 |
Completed |
NanoCarrier Co., Ltd. |
2019-03-01 |
| NCT03096184 |
A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers |
https://ClinicalTrials.gov/show/NCT03096184 |
Active, not recruiting |
Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University |
2018-07-31 |
| NCT03094169 |
AVID100 in Advanced Epithelial Carcinomas |
https://ClinicalTrials.gov/show/NCT03094169 |
Recruiting |
Formation Biologics |
2020-09-01 |
| NCT03083873 |
Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck |
https://ClinicalTrials.gov/show/NCT03083873 |
Recruiting |
Iovance Biotherapeutics, Inc. |
2021-06-30 |
| NCT03082534 |
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03082534 |
Recruiting |
University of California, San Diego |
2019-12-30 |
| NCT03076281 |
Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT03076281 |
Active, not recruiting |
Thomas Jefferson University |
2018-12-03 |
| NCT03070366 |
Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC |
https://ClinicalTrials.gov/show/NCT03070366 |
Recruiting |
Groupe Oncologie Radiotherapie Tete et Cou |
2020-07-31 |
| NCT03057613 |
The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck |
https://ClinicalTrials.gov/show/NCT03057613 |
Recruiting |
Case Comprehensive Cancer Center |
2020-08-15 |
| NCT03053466 |
APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors |
https://ClinicalTrials.gov/show/NCT03053466 |
Active, not recruiting |
Apollomics (Australia) Pty. Ltd. |
2020-02-29 |
| NCT03049618 |
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 |
https://ClinicalTrials.gov/show/NCT03049618 |
Recruiting |
University of Southern California |
2021-03-10 |
| NCT03040999 |
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412) |
https://ClinicalTrials.gov/show/NCT03040999 |
Active, not recruiting |
Merck Sharp & Dohme Corp. |
2021-04-16 |
| NCT03032250 |
Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer |
https://ClinicalTrials.gov/show/NCT03032250 |
Completed |
Wake Forest University Health Sciences |
2020-04-10 |
| NCT03022409 |
A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC). |
https://ClinicalTrials.gov/show/NCT03022409 |
Active, not recruiting |
AstraZeneca |
2020-08-31 |
| NCT02997332 |
Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT02997332 |
Recruiting |
Gustave Roussy, Cancer Campus, Grand Paris |
2019-12-31 |
| NCT02955290 |
CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT02955290 |
Recruiting |
Roswell Park Cancer Institute |
2022-06-09 |
| NCT02952586 |
Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) |
https://ClinicalTrials.gov/show/NCT02952586 |
Active, not recruiting |
Pfizer |
2019-12-23 |
| NCT02949700 |
Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT02949700 |
Recruiting |
Baylor College of Medicine |
2020-12-31 |
| NCT02938273 |
Bioimmunoradiotherapy (Cetuximab/RT/Avelumab) |
https://ClinicalTrials.gov/show/NCT02938273 |
Completed |
The Netherlands Cancer Institute |
2019-06-26 |
| NCT02923258 |
Postoperative CCRT With Docetaxel vs Cisplatin in High Risk HNSCC |
https://ClinicalTrials.gov/show/NCT02923258 |
Recruiting |
Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University |
2020-12-31 |
| NCT02915432 |
The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC |
https://ClinicalTrials.gov/show/NCT02915432 |
Active, not recruiting |
Shanghai Junshi Bioscience Co., Ltd. |
2019-09-30 |
| NCT02901483 |
A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT02901483 |
Recruiting |
PharmaEngine |
2020-12-31 |
| NCT02892201 |
Pembrolizumab in HNSCC With Residual Disease After Radiation |
https://ClinicalTrials.gov/show/NCT02892201 |
Active, not recruiting |
Yale University |
2020-01-31 |
| NCT02882308 |
Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck. |
https://ClinicalTrials.gov/show/NCT02882308 |
Completed |
Hellenic Cooperative Oncology Group |
2019-12-31 |
| NCT02862678 |
Predictive Value of Diffusion-weighted MRI Performed in Early Post-treatment in the Occurrence of Tumor Recurrence or Progression in Head and Neck Squamous Cell Carcinoma Treated With Chemoradiotherapy: a Pilot Study |
https://ClinicalTrials.gov/show/NCT02862678 |
Completed |
CHU de Reims |
2019-03-23 |
| NCT02841748 |
A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study |
https://ClinicalTrials.gov/show/NCT02841748 |
Recruiting |
University of Chicago |
2020-12-20 |
| NCT02823574 |
Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT02823574 |
Active, not recruiting |
Bristol-Myers Squibb |
2019-01-23 |
| NCT02822482 |
Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss |
https://ClinicalTrials.gov/show/NCT02822482 |
Active, not recruiting |
UNICANCER |
2019-11-30 |
| NCT02812524 |
Ipilimumab for Head and Neck Cancer Patients |
https://ClinicalTrials.gov/show/NCT02812524 |
Recruiting |
Providence Health & Services |
2020-11-30 |
| NCT02794675 |
Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT02794675 |
Completed |
Case Comprehensive Cancer Center |
2019-01-27 |
| NCT02777385 |
Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT02777385 |
Recruiting |
University of Pittsburgh |
2021-06-30 |
| NCT02776137 |
Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and Neck |
https://ClinicalTrials.gov/show/NCT02776137 |
Active, not recruiting |
Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University |
2017-12-31 |
| NCT02775812 |
Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT02775812 |
Active, not recruiting |
National Cancer Institute (NCI) |
2018-12-03 |
| NCT02769520 |
Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck |
https://ClinicalTrials.gov/show/NCT02769520 |
Recruiting |
University of California, San Diego |
2020-06-30 |
| NCT02765503 |
Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial |
https://ClinicalTrials.gov/show/NCT02765503 |
Recruiting |
International Atomic Energy Agency |
2020-11-30 |
| NCT02764593 |
Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT02764593 |
Active, not recruiting |
RTOG Foundation, Inc. |
2018-09-25 |
| NCT02762513 |
Expansion Trial for Axitinib In Head And Neck Cancer |
https://ClinicalTrials.gov/show/NCT02762513 |
Active, not recruiting |
University of Michigan Rogel Cancer Center |
2020-04-09 |
| NCT02752932 |
TumorGraft- Guided Therapy for Improved Outcomes in Head and Neck Squamous Cell Cancer- A Feasibility Study |
https://ClinicalTrials.gov/show/NCT02752932 |
Completed |
Lawson Health Research Institute |
2017-10-12 |
| NCT02741570 |
Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT02741570 |
Active, not recruiting |
Bristol-Myers Squibb |
2021-02-04 |
| NCT02734537 |
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery |
https://ClinicalTrials.gov/show/NCT02734537 |
Recruiting |
Eastern Cooperative Oncology Group |
2022-05-01 |
| NCT02715596 |
Changes in Body Composition After EPA Supplementation in Head and Neck Patients |
https://ClinicalTrials.gov/show/NCT02715596 |
Completed |
Institut Català d’Oncologia |
2019-03-01 |
| NCT02707588 |
Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC |
https://ClinicalTrials.gov/show/NCT02707588 |
Active, not recruiting |
Groupe Oncologie Radiotherapie Tete et Cou |
2020-08-31 |
| NCT02684253 |
Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) |
https://ClinicalTrials.gov/show/NCT02684253 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-02-28 |
| NCT02678884 |
Head and Neck Squamous Cell Carcinoma (HNSCC)PET-CT Pilot Study |
https://ClinicalTrials.gov/show/NCT02678884 |
Recruiting |
University Health Network, Toronto |
2028-11-30 |
| NCT02643550 |
Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT02643550 |
Recruiting |
Innate Pharma |
2021-09-30 |
| NCT02643303 |
A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers |
https://ClinicalTrials.gov/show/NCT02643303 |
Recruiting |
Ludwig Institute for Cancer Research |
2022-08-31 |
| NCT02641093 |
Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT02641093 |
Recruiting |
University of Cincinnati |
2020-06-30 |
| NCT02639858 |
Study to Evaluate the Efficacy and Safety of Docetaxel Polymeric Micelle (PM) in Recurrent or Metastatic HNSCC |
https://ClinicalTrials.gov/show/NCT02639858 |
Recruiting |
Samyang Biopharmaceuticals Corporation |
2020-09-30 |
| NCT02636036 |
Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors |
https://ClinicalTrials.gov/show/NCT02636036 |
Recruiting |
PsiOxus Therapeutics Ltd |
2021-12-31 |
| NCT02626000 |
Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137) |
https://ClinicalTrials.gov/show/NCT02626000 |
Active, not recruiting |
Amgen |
2017-11-02 |
| NCT02608736 |
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid |
https://ClinicalTrials.gov/show/NCT02608736 |
Completed |
Barretos Cancer Hospital |
2016-12-31 |
| NCT02582008 |
Bupropion Hydrochloride or Patient’s Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy |
https://ClinicalTrials.gov/show/NCT02582008 |
Active, not recruiting |
Wake Forest University Health Sciences |
2019-09-28 |
| NCT04139057 |
EBV-Specific Anti-PD1 TCR-T Cells in the Treatment of EBV-Positive NHSCC |
https://ClinicalTrials.gov/show/NCT04139057 |
Recruiting |
Xinqiao Hospital of Chongqing |
2022-02-28 |
| NCT02002182 |
ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer |
https://ClinicalTrials.gov/show/NCT02002182 |
Active, not recruiting |
Baylor College of Medicine |
2022-08-31 |
| NCT02575404 |
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients |
https://ClinicalTrials.gov/show/NCT02575404 |
Recruiting |
Providence Health & Services |
2020-10-31 |
| NCT02573493 |
Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) |
https://ClinicalTrials.gov/show/NCT02573493 |
Active, not recruiting |
Washington University School of Medicine |
2019-12-12 |
| NCT03153982 |
Ruxolitinib in Operable Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT03153982 |
Recruiting |
University of California, San Francisco |
2022-06-30 |
| NCT03138889 |
A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Select Advanced or Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT03138889 |
Recruiting |
Nektar Therapeutics |
2021-06-30 |
| NCT02376699 |
Safety Study of SEA-CD40 in Cancer Patients |
https://ClinicalTrials.gov/show/NCT02376699 |
Recruiting |
Seattle Genetics, Inc. |
2021-10-31 |
| NCT02158234 |
Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck |
https://ClinicalTrials.gov/show/NCT02158234 |
Active, not recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2021-09-30 |
| NCT02035527 |
Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT02035527 |
Completed |
Ohio State University Comprehensive Cancer Center |
2017-04-20 |
| NCT02567422 |
M6620, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT02567422 |
Recruiting |
National Cancer Institute (NCI) |
2021-09-12 |
| NCT02565758 |
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT02565758 |
Completed |
AbbVie |
2019-03-25 |
| NCT03396718 |
De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas |
https://ClinicalTrials.gov/show/NCT03396718 |
Recruiting |
Technische Universität Dresden |
2026-01-31 |
| NCT02551159 |
Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT02551159 |
Active, not recruiting |
AstraZeneca |
2020-06-30 |
| NCT02544880 |
PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC |
https://ClinicalTrials.gov/show/NCT02544880 |
Active, not recruiting |
University of Miami |
2019-06-02 |
| NCT02538510 |
Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT02538510 |
Active, not recruiting |
University of Washington |
2019-09-28 |
| NCT02537223 |
Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT02537223 |
Active, not recruiting |
University Health Network, Toronto |
2018-06-14 |
| NCT02531906 |
Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation |
https://ClinicalTrials.gov/show/NCT02531906 |
Completed |
Roswell Park Cancer Institute |
2018-06-14 |
| NCT02510872 |
Performance of PET 18 F-FDG Coupled to CT With Contrast Injection Iodized in the Diagnosis of Early Recurrences of Head and Neck Carcinoma Treated With Concurrent Chemoradiation. Comparison With 18F-FDG PET Coupled With CT Not Injected With Filling CT Standard Injection |
https://ClinicalTrials.gov/show/NCT02510872 |
Completed |
University Hospital, Caen |
2014-04-30 |
| NCT02510859 |
Nutrition and Life QUality Patients With Head and Neck Cancers |
https://ClinicalTrials.gov/show/NCT02510859 |
Completed |
University Hospital, Caen |
2014-01-31 |
| NCT02508246 |
WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT02508246 |
Completed |
University of Washington |
2018-04-26 |
| NCT02507154 |
Reactivating NK Cells in Treating Refractory Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT02507154 |
Recruiting |
National University Hospital, Singapore |
2019-08-31 |
| NCT02499328 |
Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck |
https://ClinicalTrials.gov/show/NCT02499328 |
Active, not recruiting |
AstraZeneca |
2020-02-28 |
| NCT02499120 |
Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer |
https://ClinicalTrials.gov/show/NCT02499120 |
Active, not recruiting |
Pfizer |
2018-07-19 |
| NCT02495896 |
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT02495896 |
Active, not recruiting |
University of Southern California |
2020-02-28 |
| NCT02473731 |
A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients |
https://ClinicalTrials.gov/show/NCT02473731 |
Completed |
Celldex Therapeutics |
2016-09-22 |
| NCT02454179 |
Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT02454179 |
Completed |
Acerta Pharma BV |
2018-05-31 |
| NCT02438995 |
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT02438995 |
Recruiting |
Northwell Health |
2022-07-31 |
| NCT02435602 |
The Role of Chromoendoscopy in the Early Detection of Esophageal Cancer in Patients With Prior Head and Neck Cancers |
https://ClinicalTrials.gov/show/NCT02435602 |
Completed |
Maria Sklodowska-Curie Institute - Oncology Center |
2016-11-30 |
| NCT02432963 |
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy |
https://ClinicalTrials.gov/show/NCT02432963 |
Active, not recruiting |
City of Hope Medical Center |
2020-02-29 |
| NCT02383966 |
Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT02383966 |
Active, not recruiting |
Merck KGaA, Darmstadt, Germany |
2018-01-19 |
| NCT02381535 |
Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin |
https://ClinicalTrials.gov/show/NCT02381535 |
Active, not recruiting |
National Cancer Institute (NCI) |
2020-09-30 |
| NCT02369874 |
Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT02369874 |
Active, not recruiting |
AstraZeneca |
2018-09-10 |
| NCT02369458 |
Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Platin, 5-FU, Cetuximab, and Taxane |
https://ClinicalTrials.gov/show/NCT02369458 |
Recruiting |
Washington University School of Medicine |
2021-06-30 |
| NCT02352792 |
Hypoxia-based Dose Escalation With Radiochemotherapy in Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT02352792 |
Recruiting |
University Hospital Tuebingen |
2017-12-31 |
| NCT02350712 |
Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT02350712 |
Completed |
Daiichi Sankyo, Inc. |
2016-03-31 |
| NCT02347332 |
Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT02347332 |
Completed |
Pierre Fabre Medicament |
2017-10-20 |
| NCT03386357 |
Radiotherapy With Pembrolizumab in Metastatic HNSCC |
https://ClinicalTrials.gov/show/NCT03386357 |
Recruiting |
University of Erlangen-Nürnberg Medical School |
2021-12-31 |
| NCT02335918 |
A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT02335918 |
Completed |
Celldex Therapeutics |
2018-12-12 |
| NCT02325401 |
Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT02325401 |
Completed |
University of Cincinnati |
2017-12-26 |
| NCT02319044 |
Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT02319044 |
Active, not recruiting |
AstraZeneca |
2016-09-26 |
| NCT02318771 |
Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer |
https://ClinicalTrials.gov/show/NCT02318771 |
Active, not recruiting |
Thomas Jefferson University |
2020-12-31 |
| NCT02296684 |
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT02296684 |
Recruiting |
Washington University School of Medicine |
2021-12-31 |
| NCT02289209 |
Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck |
https://ClinicalTrials.gov/show/NCT02289209 |
Recruiting |
University of Pittsburgh |
2020-12-31 |
| NCT02277197 |
Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) |
https://ClinicalTrials.gov/show/NCT02277197 |
Completed |
University of Pittsburgh |
2016-06-30 |
| NCT02270814 |
Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT02270814 |
Active, not recruiting |
Washington University School of Medicine |
2020-11-30 |
| NCT02268695 |
Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC |
https://ClinicalTrials.gov/show/NCT02268695 |
Active, not recruiting |
Groupe Oncologie Radiotherapie Tete et Cou |
2019-01-31 |
| NCT02262741 |
A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT02262741 |
Completed |
MedImmune LLC |
2017-09-21 |
| NCT02255097 |
Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055) |
https://ClinicalTrials.gov/show/NCT02255097 |
Active, not recruiting |
Merck Sharp & Dohme Corp. |
2016-04-22 |
| NCT02254018 |
Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT02254018 |
Completed |
Boehringer Ingelheim |
2005-02-28 |
| NCT02216916 |
Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy |
https://ClinicalTrials.gov/show/NCT02216916 |
Recruiting |
Yonsei University |
2019-07-31 |
| NCT02207530 |
Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT02207530 |
Active, not recruiting |
AstraZeneca |
2016-09-26 |
| NCT02207439 |
A Phase II Trial of a Protease Inhibitor, Nelfinavir (NFV), Given With Definitive, Concurrent Chemoradiotherapy (CTRT) in Patients With Locally-Advanced, Human Papilloma Virus (HPV) Negative, Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT02207439 |
Active, not recruiting |
Abramson Cancer Center of the University of Pennsylvania |
2020-12-31 |
| NCT02178072 |
Window Trial 5-aza in HNSCC, T-tare |
https://ClinicalTrials.gov/show/NCT02178072 |
Recruiting |
Yale University |
2020-11-30 |
| NCT02163057 |
Study of HPV Specific Immunotherapy in Patients With HPV Associated Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT02163057 |
Completed |
Inovio Pharmaceuticals |
2017-01-23 |
| NCT02145312 |
An Open Label, Single Arm, Multicenter Phase II Study of BYL719 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy. |
https://ClinicalTrials.gov/show/NCT02145312 |
Recruiting |
Yonsei University |
2019-05-31 |
| NCT02113878 |
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck |
https://ClinicalTrials.gov/show/NCT02113878 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2020-12-31 |
| NCT02105636 |
Trial of Nivolumab vs Therapy of Investigator’s Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) |
https://ClinicalTrials.gov/show/NCT02105636 |
Active, not recruiting |
Bristol-Myers Squibb |
2015-11-06 |
| NCT02101034 |
PD 0332991 and Cetuximab in Patients With Incurable SCCHN |
https://ClinicalTrials.gov/show/NCT02101034 |
Active, not recruiting |
Washington University School of Medicine |
2020-09-30 |
| NCT02061631 |
Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck |
https://ClinicalTrials.gov/show/NCT02061631 |
Completed |
Sanofi |
2015-07-31 |
| NCT01307267 |
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab |
https://ClinicalTrials.gov/show/NCT01307267 |
Completed |
Pfizer |
2019-02-20 |
| NCT01283334 |
A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT01283334 |
Completed |
Emory University |
2013-11-30 |
| NCT01280318 |
Profile of Plasma Growth Factors Before and After Head and Neck Oncological or Non-oncological Surgery |
https://ClinicalTrials.gov/show/NCT01280318 |
Completed |
Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
2011-12-31 |
| NCT02057107 |
Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
https://ClinicalTrials.gov/show/NCT02057107 |
Active, not recruiting |
University of Pittsburgh |
2020-12-31 |
| NCT02047201 |
Assessing Tumor Response and IMRT Treat Plan After IC Based on FDG-PET/CT for Locally Advanced HNSCC |
https://ClinicalTrials.gov/show/NCT02047201 |
Completed |
Lithuanian University of Health Sciences |
2016-01-31 |
| NCT02031250 |
Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer |
https://ClinicalTrials.gov/show/NCT02031250 |
Active, not recruiting |
University of Michigan Rogel Cancer Center |
2020-12-31 |
| NCT04196283 |
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT04196283 |
Recruiting |
AbbVie |
2022-05-16 |
| NCT03174275 |
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03174275 |
Recruiting |
UNC Lineberger Comprehensive Cancer Center |
2021-09-01 |
| NCT02585973 |
Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC |
https://ClinicalTrials.gov/show/NCT02585973 |
Active, not recruiting |
UNC Lineberger Comprehensive Cancer Center |
2020-11-30 |
| NCT02022098 |
Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial |
https://ClinicalTrials.gov/show/NCT02022098 |
Active, not recruiting |
Debiopharm International SA |
2022-04-30 |
| NCT03358472 |
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) |
https://ClinicalTrials.gov/show/NCT03358472 |
Active, not recruiting |
Incyte Corporation |
2018-07-19 |
| NCT03258554 |
Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin |
https://ClinicalTrials.gov/show/NCT03258554 |
Recruiting |
National Cancer Institute (NCI) |
2025-12-31 |
| NCT01612351 |
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery |
https://ClinicalTrials.gov/show/NCT01612351 |
Active, not recruiting |
UNC Lineberger Comprehensive Cancer Center |
2016-11-30 |
| NCT01412229 |
Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT01412229 |
Active, not recruiting |
UNC Lineberger Comprehensive Cancer Center |
2015-06-30 |
| NCT02001623 |
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors |
https://ClinicalTrials.gov/show/NCT02001623 |
Completed |
Genmab |
2019-05-02 |
| NCT01998542 |
Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck |
https://ClinicalTrials.gov/show/NCT01998542 |
Completed |
Immunovative Therapies, Ltd. |
2017-06-01 |
| NCT01979211 |
Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT01979211 |
Active, not recruiting |
University of Cincinnati |
2021-01-31 |
| NCT01967927 |
Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial Pressure to Increase Translation of Solid Tumor Therapy |
https://ClinicalTrials.gov/show/NCT01967927 |
Active, not recruiting |
University of Arkansas |
2020-06-30 |
| NCT01950689 |
NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab) |
https://ClinicalTrials.gov/show/NCT01950689 |
Active, not recruiting |
The Christie NHS Foundation Trust |
2020-11-30 |
| NCT01941992 |
Role of SAMITAL® in the Relief of Chemo-radiation (CT-RT) Induced Oral Mucositis in Head and Neck Cancer Patients |
https://ClinicalTrials.gov/show/NCT01941992 |
Completed |
Istituto Oncologico Veneto IRCCS |
2016-12-31 |
| NCT01931150 |
Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT |
https://ClinicalTrials.gov/show/NCT01931150 |
Completed |
Memorial Sloan Kettering Cancer Center |
2015-09-30 |
| NCT01927744 |
Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection |
https://ClinicalTrials.gov/show/NCT01927744 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-12-31 |
| NCT01911598 |
A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN) |
https://ClinicalTrials.gov/show/NCT01911598 |
Completed |
Genentech, Inc. |
2017-06-22 |
| NCT01864850 |
Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCC |
https://ClinicalTrials.gov/show/NCT01864850 |
Active, not recruiting |
Groupe Oncologie Radiotherapie Tete et Cou |
2020-05-31 |
| NCT01846091 |
Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer |
https://ClinicalTrials.gov/show/NCT01846091 |
Active, not recruiting |
Mayo Clinic |
2019-09-18 |
| NCT01836029 |
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT01836029 |
Completed |
Celgene |
2016-04-13 |
| NCT01824823 |
Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence |
https://ClinicalTrials.gov/show/NCT01824823 |
Active, not recruiting |
Eastern Cooperative Oncology Group |
2015-12-13 |
| NCT01807546 |
Oral Rigosertib for Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01807546 |
Completed |
Onconova Therapeutics, Inc. |
2015-03-31 |
| NCT01794481 |
Benefits of Exercise Training in Head and Neck Cancer Patients Undergoing Organ-Preserving Definitive Therapy |
https://ClinicalTrials.gov/show/NCT01794481 |
Completed |
University of Michigan Rogel Cancer Center |
2014-08-31 |
| NCT01783587 |
Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT01783587 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2020-06-30 |
| NCT01774760 |
Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT01774760 |
Completed |
Turku University Hospital |
2016-09-30 |
| NCT01758731 |
Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History |
https://ClinicalTrials.gov/show/NCT01758731 |
Completed |
University of Colorado, Denver |
2016-12-05 |
| NCT01737008 |
Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT01737008 |
Completed |
University Health Network, Toronto |
2015-02-28 |
| NCT01727076 |
Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT01727076 |
Completed |
National Cancer Institute (NCI) |
2016-06-30 |
| NCT01716416 |
Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) |
https://ClinicalTrials.gov/show/NCT01716416 |
Completed |
Washington University School of Medicine |
2015-07-31 |
| NCT01711541 |
Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT01711541 |
Active, not recruiting |
National Cancer Institute (NCI) |
2018-02-15 |
| NCT01697800 |
A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract |
https://ClinicalTrials.gov/show/NCT01697800 |
Completed |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2014-07-14 |
| NCT01696955 |
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT01696955 |
Completed |
National Cancer Institute (NCI) |
2017-05-05 |
| NCT01695122 |
Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01695122 |
Completed |
Instituto do Cancer do Estado de São Paulo |
2014-11-30 |
| NCT03349710 |
Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT03349710 |
Completed |
Bristol-Myers Squibb |
2019-10-14 |
| NCT01598077 |
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer |
https://ClinicalTrials.gov/show/NCT01598077 |
Completed |
Novartis |
2014-03-31 |
| NCT01592721 |
Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01592721 |
Active, not recruiting |
The University of Texas Health Science Center at San Antonio |
2024-01-31 |
| NCT01588431 |
Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT01588431 |
Active, not recruiting |
The University of Texas Health Science Center at San Antonio |
2021-12-31 |
| NCT01581970 |
Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer |
https://ClinicalTrials.gov/show/NCT01581970 |
Completed |
Masonic Cancer Center, University of Minnesota |
2015-09-30 |
| NCT01577173 |
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck |
https://ClinicalTrials.gov/show/NCT01577173 |
Completed |
Genentech, Inc. |
2015-06-30 |
| NCT01538381 |
Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT01538381 |
Completed |
European Organisation for Research and Treatment of Cancer - EORTC |
2015-08-31 |
| NCT01528163 |
Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT01528163 |
Completed |
Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
2014-11-30 |
| NCT01515137 |
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01515137 |
Completed |
University of Pittsburgh |
2014-09-30 |
| NCT01484847 |
A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01484847 |
Completed |
University Health Network, Toronto |
2013-03-31 |
| NCT01469546 |
Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer |
https://ClinicalTrials.gov/show/NCT01469546 |
Completed |
University of Michigan Rogel Cancer Center |
2015-04-30 |
| NCT01468896 |
Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT01468896 |
Active, not recruiting |
National Cancer Institute (NCI) |
2015-09-29 |
| NCT01458392 |
Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT01458392 |
Completed |
Acceleron Pharma, Inc. |
2015-06-30 |
| NCT01449201 |
PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01449201 |
Completed |
Yonsei University |
2013-10-31 |
| NCT01427478 |
Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT01427478 |
Active, not recruiting |
Centre Leon Berard |
2021-11-30 |
| NCT01425736 |
Nimotuzumab in Combination With TPF(Cisplatin ,Fluorouracil and Docetaxel) for Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01425736 |
Completed |
Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University |
2011-01-31 |
| NCT01417936 |
Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy |
https://ClinicalTrials.gov/show/NCT01417936 |
Completed |
Symphogen A/S |
2012-10-31 |
| NCT01415674 |
Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients |
https://ClinicalTrials.gov/show/NCT01415674 |
Completed |
UNICANCER |
2015-07-31 |
| NCT01386632 |
Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma |
https://ClinicalTrials.gov/show/NCT01386632 |
Active, not recruiting |
Sanford Health |
2014-08-31 |
| NCT01379339 |
Cabazitaxel - PF Induction Chemotherapy |
https://ClinicalTrials.gov/show/NCT01379339 |
Completed |
Icahn School of Medicine at Mount Sinai |
2015-01-31 |
| NCT01353625 |
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. |
https://ClinicalTrials.gov/show/NCT01353625 |
Active, not recruiting |
Celgene |
2020-12-28 |
| NCT01344356 |
Stereotactic Body Radiotherapy for Head and Neck Tumors |
https://ClinicalTrials.gov/show/NCT01344356 |
Completed |
Mercy Research |
2018-05-31 |
| NCT01332266 |
E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT01332266 |
Completed |
Eisai Inc. |
2016-01-31 |
| NCT04413214 |
Carrimycin in Patients With Locally Advanced, Recurrent, or Metastatic HNSCC (Non NPC): A Phase I Trial |
https://ClinicalTrials.gov/show/NCT04413214 |
Recruiting |
Shanghai Jiao Tong University School of Medicine |
2020-12-31 |
| NCT04399785 |
Phase II Study for Combination of Camrelizumab and SBRT in the First-line Treatment for R/M HNSCC |
https://ClinicalTrials.gov/show/NCT04399785 |
Recruiting |
West China Hospital |
2021-12-01 |
| NCT04397341 |
Biweekly TPF Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of Head and Neck |
https://ClinicalTrials.gov/show/NCT04397341 |
Completed |
China Medical University Hospital |
2016-08-30 |
| NCT04361409 |
Rituximab Plus Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT04361409 |
Completed |
China Medical University Hospital |
2016-11-30 |
| NCT04348916 |
Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors |
https://ClinicalTrials.gov/show/NCT04348916 |
Recruiting |
Oncorus, Inc. |
2023-06-30 |
| NCT04344795 |
Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors |
https://ClinicalTrials.gov/show/NCT04344795 |
Recruiting |
Tempest Therapeutics |
2021-08-31 |
| NCT04326257 |
Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy |
https://ClinicalTrials.gov/show/NCT04326257 |
Recruiting |
University of Pittsburgh |
2022-03-01 |
| NCT04284540 |
Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT04284540 |
Recruiting |
Icahn School of Medicine at Mount Sinai |
2024-05-31 |
| NCT04282109 |
Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX) |
https://ClinicalTrials.gov/show/NCT04282109 |
Recruiting |
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello |
2023-08-31 |
| NCT04278092 |
Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure |
https://ClinicalTrials.gov/show/NCT04278092 |
Recruiting |
Medical University of Vienna |
2021-12-31 |
| NCT04266470 |
Monitoring Blood Flow and Metabolic Activity in Malignant Tissue of Head and Neck Region |
https://ClinicalTrials.gov/show/NCT04266470 |
Recruiting |
Wake Forest University Health Sciences |
2020-12-31 |
| NCT04253808 |
Feasibility of a Carbohydrate-restricted, High-fat Diet on Head and Neck Squamous Cell Carcinoma Outcomes |
https://ClinicalTrials.gov/show/NCT04253808 |
Recruiting |
University of Illinois at Urbana-Champaign |
2022-12-31 |
| NCT04247282 |
Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection |
https://ClinicalTrials.gov/show/NCT04247282 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2022-08-31 |
| NCT04242173 |
Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC |
https://ClinicalTrials.gov/show/NCT04242173 |
Recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2022-01-31 |
| NCT04234113 |
Study of SO-C101 and SO-C101in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT04234113 |
Recruiting |
Sotio a.s. |
2022-03-31 |
| NCT04222543 |
Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging |
https://ClinicalTrials.gov/show/NCT04222543 |
Recruiting |
Radboud University |
2022-09-01 |
| NCT04220775 |
Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer |
https://ClinicalTrials.gov/show/NCT04220775 |
Recruiting |
M.D. Anderson Cancer Center |
2021-08-31 |
| NCT04213404 |
Ribociclib and Spartalizumab in R/M HNSCC |
https://ClinicalTrials.gov/show/NCT04213404 |
Recruiting |
National Taiwan University Hospital |
2024-01-31 |
| NCT04193293 |
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT04193293 |
Recruiting |
Verastem, Inc. |
2021-11-30 |
| NCT04183166 |
A Clinical Trial Evaluating TG4050 in Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT04183166 |
Recruiting |
Transgene |
2021-11-30 |
| NCT04164238 |
Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined With Chemotherapy in HNSCC Patients |
https://ClinicalTrials.gov/show/NCT04164238 |
Recruiting |
First Affiliated Hospital of Zhejiang University |
2020-11-07 |
| NCT04152018 |
Study of PF‑06940434 in Patients With Advanced or Metastatic Solid Tumors. |
https://ClinicalTrials.gov/show/NCT04152018 |
Recruiting |
Pfizer |
2024-03-02 |
| NCT04146402 |
SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT04146402 |
Recruiting |
Sinocelltech Ltd. |
2022-01-29 |
| NCT04144517 |
A Study of ALKS 4230 With Pembrolizumab in Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT04144517 |
Recruiting |
Alkermes, Inc. |
2021-09-30 |
| NCT04117139 |
The Diagnostic Value of PET/MRI in Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT04117139 |
Recruiting |
Odense University Hospital |
2021-09-30 |
| NCT04110249 |
Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT04110249 |
Recruiting |
Roswell Park Cancer Institute |
2020-07-13 |
| NCT04098458 |
Navigation for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC |
https://ClinicalTrials.gov/show/NCT04098458 |
Completed |
Medical University of South Carolina |
2020-04-14 |
| NCT04096638 |
Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT04096638 |
Recruiting |
Spring Bank Pharmaceuticals, Inc. |
2021-12-31 |
| NCT04091867 |
sEphB4-HSA With Cetuximab and RT in Patients With High Risk, LAHNSCC and Heavy Smoking Histories |
https://ClinicalTrials.gov/show/NCT04091867 |
Recruiting |
University of Colorado, Denver |
2021-09-30 |
| NCT04080804 |
Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT04080804 |
Recruiting |
University of Pittsburgh |
2021-07-31 |
| NCT04052204 |
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT04052204 |
Recruiting |
Pfizer |
2022-10-09 |
| NCT04045496 |
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT04045496 |
Recruiting |
Jacobio Pharmaceuticals Co., Ltd. |
2021-03-31 |
| NCT04042935 |
Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC |
https://ClinicalTrials.gov/show/NCT04042935 |
Recruiting |
University of Colorado, Denver |
2020-12-07 |
| NCT04034225 |
Addition of SNS-301 to Ongoing Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN |
https://ClinicalTrials.gov/show/NCT04034225 |
Recruiting |
Sensei Biotherapeutics, Inc. |
2021-02-01 |
| NCT04030130 |
Navigation vs Usual Care for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC |
https://ClinicalTrials.gov/show/NCT04030130 |
Recruiting |
Medical University of South Carolina |
2024-08-31 |
| NCT04007744 |
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT04007744 |
Recruiting |
Mayo Clinic |
2021-07-31 |
| NCT04001543 |
Efficacy of an Oral Immunomodulatory Nutrient on Survival During Postoperative Concomitant Chemoradiotherapy in Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT04001543 |
Recruiting |
Institut du Cancer de Montpellier - Val d’Aurelle |
2025-05-31 |
| NCT04000529 |
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies |
https://ClinicalTrials.gov/show/NCT04000529 |
Recruiting |
Novartis |
2022-03-22 |
| NCT03993353 |
Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT03993353 |
Recruiting |
University of California, San Diego |
2022-12-31 |
| NCT03978689 |
A Phase 1 Study in Patients With HPV+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03978689 |
Recruiting |
Cue Biopharma |
2021-06-30 |
| NCT03953976 |
INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy |
https://ClinicalTrials.gov/show/NCT03953976 |
Recruiting |
University of Texas Southwestern Medical Center |
2022-07-31 |
| NCT03944915 |
De-Escalation Therapy for Human Papillomavirus Negative Disease |
https://ClinicalTrials.gov/show/NCT03944915 |
Recruiting |
University of Chicago |
2022-07-01 |
| NCT03942380 |
Cell-free Tumor DNA in Head and Neck Cancer Patients |
https://ClinicalTrials.gov/show/NCT03942380 |
Recruiting |
Rigshospitalet, Denmark |
2025-02-01 |
| NCT03917381 |
GEN1046 Safety Trial in Patients With Malignant Solid Tumors |
https://ClinicalTrials.gov/show/NCT03917381 |
Recruiting |
Genmab |
2021-10-31 |
| NCT03916627 |
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC |
https://ClinicalTrials.gov/show/NCT03916627 |
Recruiting |
Regeneron Pharmaceuticals |
2022-06-20 |
| NCT03896412 |
Detection of Circulating Tumor DNA in p16- Locally Advanced Head Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03896412 |
Recruiting |
Centre Henri Becquerel |
2021-05-19 |
| NCT03894618 |
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT03894618 |
Recruiting |
Shattuck Labs, Inc. |
2022-02-02 |
| NCT03880396 |
Concurrent Hypofractionated Rth With Weekly Cisplatin in Locally Advanced SCCHN |
https://ClinicalTrials.gov/show/NCT03880396 |
Active, not recruiting |
Assiut University |
2019-12-10 |
| NCT03878979 |
Preoperative Immune Checkpoint Inhibitor for Patients With Primary Untreated or Recurrent/Metastatic SCCHN |
https://ClinicalTrials.gov/show/NCT03878979 |
Recruiting |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2021-07-31 |
| NCT03874741 |
SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03874741 |
Active, not recruiting |
Sinocelltech Ltd. |
2020-06-30 |
| NCT03868020 |
Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease |
https://ClinicalTrials.gov/show/NCT03868020 |
Recruiting |
M.D. Anderson Cancer Center |
2021-08-31 |
| NCT03855384 |
Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN） |
https://ClinicalTrials.gov/show/NCT03855384 |
Recruiting |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2020-12-31 |
| NCT03849469 |
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03849469 |
Recruiting |
Xencor, Inc. |
2026-09-30 |
| NCT03838601 |
Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2 |
https://ClinicalTrials.gov/show/NCT03838601 |
Recruiting |
University Health Network, Toronto |
2020-11-02 |
| NCT03830385 |
Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin for Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck |
https://ClinicalTrials.gov/show/NCT03830385 |
Recruiting |
Sun Yat-sen University |
2021-02-15 |
| NCT03829501 |
Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer |
https://ClinicalTrials.gov/show/NCT03829501 |
Recruiting |
Kymab Limited |
2023-05-31 |
| NCT03818542 |
A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03818542 |
Recruiting |
AbbVie |
2021-03-01 |
| NCT03818061 |
Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT03818061 |
Recruiting |
Centre Leon Berard |
2022-03-01 |
| NCT03817307 |
Validation of USPIO-enhanced MRI for Detection of Lymph Node Metastases in Head and Neck Carcinoma |
https://ClinicalTrials.gov/show/NCT03817307 |
Recruiting |
Radboud University |
2020-09-30 |
| NCT03815903 |
Induction Chemotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03815903 |
Recruiting |
Barretos Cancer Hospital |
2020-12-31 |
| NCT03813836 |
Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC |
https://ClinicalTrials.gov/show/NCT03813836 |
Recruiting |
University College, London |
2021-12-31 |
| NCT03811652 |
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT03811652 |
Completed |
MedImmune LLC |
2019-12-10 |
| NCT03809624 |
Study of INBRX-105 in Patients With Solid Tumors |
https://ClinicalTrials.gov/show/NCT03809624 |
Recruiting |
Inhibrx, Inc. |
2021-07-31 |
| NCT03803774 |
Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03803774 |
Recruiting |
National Cancer Institute (NCI) |
2020-07-31 |
| NCT03799744 |
Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03799744 |
Recruiting |
Institut Català d’Oncologia |
2021-09-30 |
| NCT03795610 |
Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03795610 |
Recruiting |
University of California, San Diego |
2022-06-30 |
| NCT03789097 |
Vaccination With Flt3L, Radiation, and Poly-ICLC |
https://ClinicalTrials.gov/show/NCT03789097 |
Recruiting |
Icahn School of Medicine at Mount Sinai |
2023-06-30 |
| NCT03788785 |
Smoking Tobacco Cessation Integrated Program of Patients Treated for the Head and the Neck Cancer |
https://ClinicalTrials.gov/show/NCT03788785 |
Recruiting |
Assistance Publique - Hôpitaux de Paris |
2022-06-30 |
| NCT03775525 |
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT03775525 |
Recruiting |
Genzada Pharmaceuticals USA, Inc. |
2020-09-30 |
| NCT03768856 |
Temporally Feathered Radiation Therapy (TFRT) for Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03768856 |
Completed |
Case Comprehensive Cancer Center |
2019-07-18 |
| NCT03765918 |
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) |
https://ClinicalTrials.gov/show/NCT03765918 |
Recruiting |
Merck Sharp & Dohme Corp. |
2025-07-30 |
| NCT03758781 |
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT03758781 |
Recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2021-02-28 |
| NCT03752398 |
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) |
https://ClinicalTrials.gov/show/NCT03752398 |
Recruiting |
Xencor, Inc. |
2024-09-30 |
| NCT03740100 |
Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations |
https://ClinicalTrials.gov/show/NCT03740100 |
Recruiting |
PIQUR Therapeutics AG |
2020-12-31 |
| NCT03739931 |
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Patients With Advanced Malignancies |
https://ClinicalTrials.gov/show/NCT03739931 |
Recruiting |
ModernaTX, Inc. |
2020-06-30 |
| NCT03735680 |
A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer |
https://ClinicalTrials.gov/show/NCT03735680 |
Recruiting |
OncoNano Medicine, Inc. |
2020-09-30 |
| NCT03735628 |
An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03735628 |
Recruiting |
Bayer |
2022-12-30 |
| NCT03735290 |
A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer |
https://ClinicalTrials.gov/show/NCT03735290 |
Recruiting |
Immunicum AB |
2022-12-31 |
| NCT03733210 |
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT03733210 |
Recruiting |
Stanford University |
2021-02-07 |
| NCT03723967 |
FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel |
https://ClinicalTrials.gov/show/NCT03723967 |
Recruiting |
Centre Leon Berard |
2022-03-15 |
| NCT03720158 |
Enteral Omega 3 During Radiotherapy to Improve the Quality of Life and Functionality of Head and Neck Cancer Patients |
https://ClinicalTrials.gov/show/NCT03720158 |
Recruiting |
Coordinación de Investigación en Salud, Mexico |
2021-12-31 |
| NCT03719690 |
Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy |
https://ClinicalTrials.gov/show/NCT03719690 |
Recruiting |
Kura Oncology, Inc. |
2021-05-31 |
| NCT03715946 |
Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer |
https://ClinicalTrials.gov/show/NCT03715946 |
Recruiting |
University of Pittsburgh |
2021-05-31 |
| NCT03713372 |
Safety and Efficacy of SCT200 in Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03713372 |
Active, not recruiting |
Sinocelltech Ltd. |
2020-02-11 |
| NCT03695510 |
Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study) |
https://ClinicalTrials.gov/show/NCT03695510 |
Recruiting |
National Taiwan University Hospital |
2021-04-30 |
| NCT03691714 |
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03691714 |
Recruiting |
University of Cincinnati |
2021-10-31 |
| NCT03690986 |
VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT03690986 |
Recruiting |
Emory University |
2020-11-30 |
| NCT03689192 |
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT03689192 |
Recruiting |
Herlev Hospital |
2020-12-31 |
| NCT03684785 |
Intratumoral AST-008 Combined With Pembrolizumab or Cemiplimab in Patients With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03684785 |
Recruiting |
Exicure, Inc. |
2021-06-30 |
| NCT03665285 |
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT03665285 |
Recruiting |
NextCure, Inc. |
2021-05-01 |
| NCT03655444 |
Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy |
https://ClinicalTrials.gov/show/NCT03655444 |
Recruiting |
Washington University School of Medicine |
2022-06-30 |
| NCT03652077 |
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies |
https://ClinicalTrials.gov/show/NCT03652077 |
Recruiting |
Incyte Corporation |
2021-01-31 |
| NCT03650764 |
Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03650764 |
Recruiting |
Washington University School of Medicine |
2021-11-30 |
| NCT03649048 |
Low-Dose Weekly vs High-Dose Cisplatin |
https://ClinicalTrials.gov/show/NCT03649048 |
Recruiting |
Lawson Health Research Institute |
2021-02-28 |
| NCT03647163 |
Combination Therapy With Intravenous VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and HNSCC |
https://ClinicalTrials.gov/show/NCT03647163 |
Recruiting |
Vyriad, Inc. |
2020-11-01 |
| NCT03646461 |
Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC |
https://ClinicalTrials.gov/show/NCT03646461 |
Recruiting |
University of California, San Diego |
2021-05-30 |
| NCT03645928 |
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors |
https://ClinicalTrials.gov/show/NCT03645928 |
Recruiting |
Iovance Biotherapeutics, Inc. |
2023-12-31 |
| NCT03635164 |
Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03635164 |
Recruiting |
University of Colorado, Denver |
2020-06-25 |
| NCT03633110 |
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine |
https://ClinicalTrials.gov/show/NCT03633110 |
Active, not recruiting |
Genocea Biosciences, Inc. |
2022-12-31 |
| NCT03629756 |
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies |
https://ClinicalTrials.gov/show/NCT03629756 |
Recruiting |
Arcus Biosciences, Inc. |
2021-01-31 |
| NCT03624231 |
Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC |
https://ClinicalTrials.gov/show/NCT03624231 |
Recruiting |
Charite University, Berlin, Germany |
2021-08-31 |
| NCT03620123 |
A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT03620123 |
Recruiting |
AIO-Studien-gGmbH |
2022-07-31 |
| NCT03618654 |
Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03618654 |
Recruiting |
Thomas Jefferson University |
2020-07-31 |
| NCT03602911 |
A Comparison of NETSPOT Imaging Versus F-FDG-PET in Head and Neck Cancer Patients |
https://ClinicalTrials.gov/show/NCT03602911 |
Recruiting |
West Virginia University |
2019-07-30 |
| NCT03590054 |
A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies |
https://ClinicalTrials.gov/show/NCT03590054 |
Recruiting |
University of California, San Francisco |
2022-02-15 |
| NCT03589339 |
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy |
https://ClinicalTrials.gov/show/NCT03589339 |
Recruiting |
Nanobiotix |
2023-03-30 |
| NCT03578406 |
HPV-E6-Specific Anti-PD1 TCR-T Cells in the Treatment of HPV-Positive NHSCC or Cervical Cancer |
https://ClinicalTrials.gov/show/NCT03578406 |
Recruiting |
Xinqiao Hospital of Chongqing |
2020-08-30 |
| NCT03576417 |
A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck |
https://ClinicalTrials.gov/show/NCT03576417 |
Recruiting |
Groupe Oncologie Radiotherapie Tete et Cou |
2021-12-31 |
| NCT03575949 |
Dual-time Point (DTP) FDG PET CT for the Post-treatment Assessment of Head and Neck Tumors Following Definitive Chemoradiation Therapy |
https://ClinicalTrials.gov/show/NCT03575949 |
Recruiting |
M.D. Anderson Cancer Center |
2022-12-31 |
| NCT03575598 |
Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study |
https://ClinicalTrials.gov/show/NCT03575598 |
Recruiting |
University Health Network, Toronto |
2020-08-30 |
| NCT03574792 |
Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy |
https://ClinicalTrials.gov/show/NCT03574792 |
Recruiting |
Roswell Park Cancer Institute |
2020-09-03 |
| NCT03565783 |
Cemiplimab in Treating Participants With Recurrent Stage III-IV Head and Neck Squamous Cell Cancer Before Surgery |
https://ClinicalTrials.gov/show/NCT03565783 |
Recruiting |
M.D. Anderson Cancer Center |
2021-07-31 |
| NCT03556228 |
Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT03556228 |
Recruiting |
VM Oncology, LLC |
2021-06-30 |
| NCT03552965 |
Margin-Based Vs. Robust Photon Radiotherapy Planning in IMRT of HN-SQCC |
https://ClinicalTrials.gov/show/NCT03552965 |
Enrolling by invitation |
University of Arkansas |
2020-07-01 |
| NCT03552718 |
QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. |
https://ClinicalTrials.gov/show/NCT03552718 |
Recruiting |
NantBioScience, Inc. |
2019-12-30 |
| NCT03546582 |
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma |
https://ClinicalTrials.gov/show/NCT03546582 |
Recruiting |
RTOG Foundation, Inc. |
2024-07-31 |
| NCT03540563 |
ctDNA as a Biomarker for Treatment Response in HNSCC |
https://ClinicalTrials.gov/show/NCT03540563 |
Recruiting |
The Netherlands Cancer Institute |
2021-05-31 |
| NCT03538028 |
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies |
https://ClinicalTrials.gov/show/NCT03538028 |
Recruiting |
Incyte Corporation |
2020-09-24 |
| NCT03525392 |
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. |
https://ClinicalTrials.gov/show/NCT03525392 |
Recruiting |
Ipsen |
2021-04-20 |
| NCT03524326 |
Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03524326 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-04-30 |
| NCT03522584 |
Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03522584 |
Recruiting |
University of Washington |
2021-02-15 |
| NCT03521570 |
Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer |
https://ClinicalTrials.gov/show/NCT03521570 |
Recruiting |
Emory University |
2020-12-31 |
| NCT03519048 |
Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03519048 |
Recruiting |
Gustave Roussy, Cancer Campus, Grand Paris |
2026-01-31 |
| NCT03518671 |
Building a Renewed ImaGe After Head & Neck Cancer Treatment |
https://ClinicalTrials.gov/show/NCT03518671 |
Completed |
Medical University of South Carolina |
2019-08-22 |
| NCT03517488 |
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03517488 |
Recruiting |
Xencor, Inc. |
2020-12-31 |
| NCT03510390 |
Metformin in Head and Neck Squamous Cell Carcinoma: Effect on Tissue Oxygenation |
https://ClinicalTrials.gov/show/NCT03510390 |
Recruiting |
University Hospital Inselspital, Berne |
2020-09-15 |
| NCT03509012 |
Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT03509012 |
Active, not recruiting |
AstraZeneca |
2022-04-04 |
| NCT03498378 |
Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03498378 |
Recruiting |
University of California, San Diego |
2021-08-31 |
| NCT03491176 |
Magnetic Resonance (MR) Imaging & Blood Biomarkers for Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT03491176 |
Recruiting |
M.D. Anderson Cancer Center |
2020-05-31 |
| NCT03480672 |
Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03480672 |
Recruiting |
University of Leipzig |
2022-08-31 |
| NCT03474497 |
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade |
https://ClinicalTrials.gov/show/NCT03474497 |
Recruiting |
University of California, Davis |
2021-07-01 |
| NCT03468218 |
Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer |
https://ClinicalTrials.gov/show/NCT03468218 |
Recruiting |
Emory University |
2020-11-30 |
| NCT03454451 |
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers |
https://ClinicalTrials.gov/show/NCT03454451 |
Recruiting |
Corvus Pharmaceuticals, Inc. |
2022-03-31 |
| NCT03452137 |
A Study of Atezolizumab (Anti−Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT03452137 |
Recruiting |
Hoffmann-La Roche |
2021-03-22 |
| NCT03435640 |
A Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) and With Bempegaldesleukin Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies |
https://ClinicalTrials.gov/show/NCT03435640 |
Recruiting |
Nektar Therapeutics |
2021-09-30 |
| NCT03433027 |
A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03433027 |
Completed |
Benitec BioPharma Ltd |
2018-12-12 |
| NCT03426657 |
Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC |
https://ClinicalTrials.gov/show/NCT03426657 |
Recruiting |
University of Erlangen-Nürnberg Medical School |
2021-04-30 |
| NCT03422536 |
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT03422536 |
Recruiting |
University of Arizona |
2020-12-31 |
| NCT03421912 |
Satisfaction and Quality of Life Comparison Between Patients Using Cicaplast Baume B5 Versus Dexeryl for the Management of Cutaneous Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors (iEGFR) |
https://ClinicalTrials.gov/show/NCT03421912 |
Recruiting |
Centre Leon Berard |
2019-05-31 |
| NCT03412058 |
Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists |
https://ClinicalTrials.gov/show/NCT03412058 |
Recruiting |
UNICANCER |
2020-05-31 |
| NCT01252628 |
Phase 1 and 2 Study of PX-866 and Cetuximab |
https://ClinicalTrials.gov/show/NCT01252628 |
Completed |
Seattle Genetics, Inc. |
2013-11-30 |
| NCT01218048 |
ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01218048 |
Completed |
University of Pittsburgh |
2015-11-04 |
| NCT01204099 |
Study of PX-866 and Docetaxel in Solid Tumors |
https://ClinicalTrials.gov/show/NCT01204099 |
Completed |
Seattle Genetics, Inc. |
2013-12-31 |
| NCT01195922 |
Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01195922 |
Completed |
National Institutes of Health Clinical Center (CC) |
2015-06-30 |
| NCT01177956 |
A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck |
https://ClinicalTrials.gov/show/NCT01177956 |
Completed |
Merck KGaA, Darmstadt, Germany |
2011-01-31 |
| NCT01172769 |
Efficacy Study of Temsirolimus to Treat Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT01172769 |
Completed |
Hannover Medical School |
2012-03-31 |
| NCT01154920 |
Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01154920 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-07-31 |
| NCT01115790 |
A Phase 1 Study in Participants With Advanced Cancer |
https://ClinicalTrials.gov/show/NCT01115790 |
Completed |
Eli Lilly and Company |
2016-01-31 |
| NCT01104922 |
Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT01104922 |
Active, not recruiting |
University of Pittsburgh |
2020-07-31 |
| NCT01086826 |
Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT01086826 |
Completed |
Associazione Volontari Pazienti Oncologici |
2014-04-30 |
| NCT01064479 |
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT01064479 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2021-02-28 |
| NCT01059643 |
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT01059643 |
Completed |
Eli Lilly and Company |
2012-12-31 |
| NCT01054625 |
Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
https://ClinicalTrials.gov/show/NCT01054625 |
Completed |
Genmab |
2011-07-31 |
| NCT01046266 |
A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT01046266 |
Completed |
Hoffmann-La Roche |
2012-06-30 |
| NCT01045421 |
Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies |
https://ClinicalTrials.gov/show/NCT01045421 |
Completed |
Millennium Pharmaceuticals, Inc. |
2013-05-31 |
| NCT01040832 |
EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT01040832 |
Completed |
EMD Serono |
2012-01-31 |
| NCT01012258 |
Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects |
https://ClinicalTrials.gov/show/NCT01012258 |
Completed |
Merck KGaA, Darmstadt, Germany |
2010-09-30 |
| NCT00999700 |
Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin |
https://ClinicalTrials.gov/show/NCT00999700 |
Active, not recruiting |
Gruppo Oncologico del Nord-Ovest |
2016-12-31 |
| NCT00995293 |
Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration Trial |
https://ClinicalTrials.gov/show/NCT00995293 |
Completed |
Sanofi |
2018-01-26 |
| NCT00971932 |
Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
https://ClinicalTrials.gov/show/NCT00971932 |
Completed |
Merck KGaA, Darmstadt, Germany |
2011-03-31 |
| NCT00968435 |
Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT00968435 |
Completed |
Memorial Sloan Kettering Cancer Center |
2016-08-31 |
| NCT00957853 |
Preoperative Treatment With Cetuximab and/or IMC-A12 |
https://ClinicalTrials.gov/show/NCT00957853 |
Completed |
M.D. Anderson Cancer Center |
2018-08-15 |
| NCT00957086 |
Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer |
https://ClinicalTrials.gov/show/NCT00957086 |
Recruiting |
National Cancer Centre, Singapore |
2020-06-30 |
| NCT00899054 |
Safety and Efficacy Study of P276-00 in Combination With Radiation in Subjects With Advanced Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT00899054 |
Completed |
Piramal Enterprises Limited |
2011-01-31 |
| NCT00894413 |
A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract |
https://ClinicalTrials.gov/show/NCT00894413 |
Completed |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2012-03-31 |
| NCT00865098 |
Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
https://ClinicalTrials.gov/show/NCT00865098 |
Completed |
Merck KGaA, Darmstadt, Germany |
2010-06-30 |
| NCT03405142 |
Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer |
https://ClinicalTrials.gov/show/NCT03405142 |
Recruiting |
Stanford University |
2021-02-01 |
| NCT03139058 |
Prevalence of Liver Fibrosis and Cirrhosis in Patients With Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT03139058 |
Recruiting |
Centre Hospitalier Universitaire, Amiens |
2019-06-20 |
| NCT00824343 |
A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT00824343 |
Completed |
Piramal Enterprises Limited |
2011-04-30 |
| NCT04146181 |
Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT04146181 |
Recruiting |
Sinocelltech Ltd. |
2021-06-30 |
| NCT03245736 |
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. |
https://ClinicalTrials.gov/show/NCT03245736 |
Completed |
Genmab |
2019-01-10 |
| NCT04445064 |
Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck. |
https://ClinicalTrials.gov/show/NCT04445064 |
Recruiting |
Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
2024-06-08 |
| NCT03625323 |
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC |
https://ClinicalTrials.gov/show/NCT03625323 |
Recruiting |
Immutep S.A. |
2020-12-31 |
| NCT02524275 |
Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT02524275 |
Recruiting |
University of Nebraska |
2021-06-01 |
| NCT03245489 |
Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT03245489 |
Recruiting |
Medical University of South Carolina |
2020-12-30 |
| NCT03317327 |
REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors |
https://ClinicalTrials.gov/show/NCT03317327 |
Recruiting |
Oslo University Hospital |
2023-11-02 |
| NCT03088059 |
Biomarker-based Study in R/M SCCHN |
https://ClinicalTrials.gov/show/NCT03088059 |
Recruiting |
European Organisation for Research and Treatment of Cancer - EORTC |
2021-06-30 |
| NCT02999646 |
Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC |
https://ClinicalTrials.gov/show/NCT02999646 |
Recruiting |
Swiss Group for Clinical Cancer Research |
2022-12-31 |
| NCT02658214 |
Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors |
https://ClinicalTrials.gov/show/NCT02658214 |
Completed |
AstraZeneca |
2019-11-14 |
| NCT04199104 |
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010) |
https://ClinicalTrials.gov/show/NCT04199104 |
Recruiting |
Merck Sharp & Dohme Corp. |
2023-11-13 |
| NCT02124707 |
Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN |
https://ClinicalTrials.gov/show/NCT02124707 |
Active, not recruiting |
UNC Lineberger Comprehensive Cancer Center |
2020-02-27 |
| NCT02054442 |
A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck |
https://ClinicalTrials.gov/show/NCT02054442 |
Active, not recruiting |
Radboud University |
2019-12-31 |
| NCT04440917 |
Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT04440917 |
Recruiting |
Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University |
2022-06-30 |
| NCT03998696 |
An Experimental Study to Compare Treatment Response and Toxicities of Concurrent Chemoradiation With Weekly Cisplatin and Three Weekly Cisplatin in Locally Advanced Head and Neck Cancer. |
https://ClinicalTrials.gov/show/NCT03998696 |
Completed |
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh |
2018-06-30 |
| NCT00771641 |
Fractionated Radiation Therapy in Treating Advanced Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT00771641 |
Completed |
Radiation Therapy Oncology Group |
2002-08-31 |
| NCT00756444 |
A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT00756444 |
Completed |
Amgen |
2012-03-30 |
| NCT00736944 |
Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT00736944 |
Active, not recruiting |
Washington University School of Medicine |
2010-08-31 |
| NCT00736619 |
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC) |
https://ClinicalTrials.gov/show/NCT00736619 |
Completed |
Memorial Sloan Kettering Cancer Center |
2016-08-31 |
| NCT00671437 |
Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT00671437 |
Completed |
Washington University School of Medicine |
2011-12-31 |
| NCT00625456 |
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT00625456 |
Completed |
SillaJen, Inc. |
2010-04-30 |
| NCT00623558 |
Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC) |
https://ClinicalTrials.gov/show/NCT00623558 |
Completed |
Seoul National University Hospital |
2012-11-30 |
| NCT00611754 |
Phase II Study of Oxaliplatin in Combination With 5-Fu in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT00611754 |
Completed |
Sanofi |
NA |
| NCT00609284 |
Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux |
https://ClinicalTrials.gov/show/NCT00609284 |
Completed |
Groupe Oncologie Radiotherapie Tete et Cou |
2018-03-26 |
| NCT00596219 |
Molecular Effects of Short-Term Celecoxib Treatment on Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT00596219 |
Completed |
Memorial Sloan Kettering Cancer Center |
2006-10-31 |
| NCT00547157 |
Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT00547157 |
Completed |
Amgen |
2011-12-31 |
| NCT00519077 |
Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT00519077 |
Completed |
University of Chicago |
2008-05-31 |
| NCT00513383 |
Panitumumab Chemoradiotherapy Chemotherapy for Squamous Cancer of the Head and Neck |
https://ClinicalTrials.gov/show/NCT00513383 |
Completed |
Massachusetts General Hospital |
2010-10-31 |
| NCT00496652 |
DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC |
https://ClinicalTrials.gov/show/NCT00496652 |
Completed |
Danish Head and Neck Cancer Group |
2012-07-31 |
| NCT00494182 |
Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer |
https://ClinicalTrials.gov/show/NCT00494182 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-05-31 |
| NCT00474825 |
Dose Escalation Study of Hyperbaric Oxygen With Radiation and Chemotherapy to Treat Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT00474825 |
Completed |
National Baromedical Services |
2011-02-28 |
| NCT00459043 |
Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck |
https://ClinicalTrials.gov/show/NCT00459043 |
Completed |
Dana-Farber Cancer Institute |
2010-03-31 |
| NCT00454779 |
PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response |
https://ClinicalTrials.gov/show/NCT00454779 |
Completed |
Amgen |
2012-06-11 |
| NCT00446446 |
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) |
https://ClinicalTrials.gov/show/NCT00446446 |
Completed |
Amgen |
2010-12-15 |
| NCT00442455 |
Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT00442455 |
Completed |
Grupo de Investigación ClÃnica en OncologÃa Radioterapia |
2015-08-31 |
| NCT00402545 |
C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT00402545 |
Completed |
Dana-Farber Cancer Institute |
2009-07-31 |
| NCT00371566 |
A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer |
https://ClinicalTrials.gov/show/NCT00371566 |
Completed |
GlaxoSmithKline |
2007-12-31 |
| NCT00358930 |
A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT00358930 |
Completed |
ArQule |
2007-08-31 |
| NCT00357149 |
Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS) |
https://ClinicalTrials.gov/show/NCT00357149 |
Completed |
Sanofi |
2008-02-29 |
| NCT00343083 |
Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442) |
https://ClinicalTrials.gov/show/NCT00343083 |
Completed |
University of Maryland, Baltimore |
2011-06-30 |
| NCT00318890 |
Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT00318890 |
Completed |
University of Alabama at Birmingham |
2007-04-30 |
| NCT00304278 |
Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA) |
https://ClinicalTrials.gov/show/NCT00304278 |
Completed |
Southern Illinois University |
2015-05-31 |
| NCT00268671 |
Docetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN) |
https://ClinicalTrials.gov/show/NCT00268671 |
Completed |
Sanofi |
2006-04-30 |
| NCT00258310 |
Ph II Study Examining Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation &/or Chemotherapy |
https://ClinicalTrials.gov/show/NCT00258310 |
Completed |
Barbara Ann Karmanos Cancer Institute |
2011-02-28 |
| NCT00257738 |
0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT00257738 |
Completed |
University of Maryland, Baltimore |
2012-10-31 |
| NCT00229723 |
IRESSAâ„¢ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma |
https://ClinicalTrials.gov/show/NCT00229723 |
Completed |
AstraZeneca |
NA |
| NCT00210470 |
A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT00210470 |
Completed |
Brooklyn ImmunoTherapeutics, LLC |
2010-12-31 |
| NCT00206752 |
Study of Unilateral Neck Irradiation in Patients With SCC of the Head and Neck |
https://ClinicalTrials.gov/show/NCT00206752 |
Completed |
Beth Israel Medical Center |
2015-02-28 |
| NCT00174837 |
TRACE: Tirapazamine-Radiation And Cisplatin Evaluation |
https://ClinicalTrials.gov/show/NCT00174837 |
Completed |
Sanofi |
2008-01-31 |
| NCT00162708 |
Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC |
https://ClinicalTrials.gov/show/NCT00162708 |
Completed |
Gustave Roussy, Cancer Campus, Grand Paris |
NA |
| NCT00139269 |
Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT00139269 |
Completed |
Dana-Farber Cancer Institute |
2006-12-31 |
| NCT00139243 |
Study of Taxotere, Cisplatin, 5-Fluorouracil, and Leucovorin for Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT00139243 |
Completed |
Dana-Farber Cancer Institute |
2006-01-31 |
| NCT00122460 |
Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME) |
https://ClinicalTrials.gov/show/NCT00122460 |
Completed |
Merck KGaA, Darmstadt, Germany |
2007-03-31 |
| NCT00084682 |
Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT00084682 |
Completed |
National Cancer Institute (NCI) |
2008-11-30 |
| NCT00103259 |
Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT00103259 |
Completed |
National Cancer Institute (NCI) |
2011-11-30 |
| NCT00096174 |
Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT00096174 |
Completed |
Eastern Cooperative Oncology Group |
2009-07-31 |
| NCT00093041 |
Zalutumumab in Head and Neck Cancer |
https://ClinicalTrials.gov/show/NCT00093041 |
Completed |
Genmab |
2005-01-31 |
| NCT00083057 |
Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT00083057 |
Completed |
National Institutes of Health Clinical Center (CC) |
2010-10-31 |
| NCT00079053 |
Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck |
https://ClinicalTrials.gov/show/NCT00079053 |
Completed |
Canadian Cancer Trials Group |
2008-12-09 |
| NCT00158652 |
Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC |
https://ClinicalTrials.gov/show/NCT00158652 |
Completed |
Groupe Oncologie Radiotherapie Tete et Cou |
2011-03-31 |
| NCT00206219 |
Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX) |
https://ClinicalTrials.gov/show/NCT00206219 |
Completed |
AstraZeneca |
2007-09-30 |